Physician profile
Stacy E Spears
NPI 1770572091
$12,496.16
in general payments reported to CMS, 2019-2025
22 companies · $3,013 in 2025
The $3,013 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,936 · 2022: $2,455 · 2023: $2,491 · 2024: $2,602 · 2025: $3,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,096 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,096.49 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,190.85 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,932.50 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,515.29 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,344.55 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,338.84 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,302.35 | 2021-2025 | Caplyta |
| Alkermes, INC. | $646.95 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Vanda Pharmaceuticals INC. | $502.43 | 2022-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $155.26 | 2024-2025 | Cobenfy |
| Indivior INC. | $113.68 | 2022-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $89.13 | 2023 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.99 | 2024 | |
| Pear Therapeutics (US), INC. | $58.89 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.36 | 2022 | |
| Exelixis INC. | $36.50 | 2022-2023 | Cabometyx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $32.98 | 2023 | Azstarys |
| Harmony Biosciences LLC | $31.02 | 2025 | |
| Sunovion Pharmaceuticals INC. | $27.99 | 2022 | |
| Lundbeck LLC | $20.92 | 2024 | Rexulti |
| Boston Scientific Corporation | $19.04 | 2023 | Varithena Administration Pack |
| Lilly USA, LLC | $17.07 | 2024 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $3.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.